Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(1):1; doi:10.1093/jnci/95.1.1
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content

Journal of the National Cancer Institute, Vol. 95, No. 1, 1, January 1, 2003
© 2003 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Responses of Cancer Patients to Placebos

Randomized controlled trials of new disease treatments, including some treatments for cancer, often include a placebo control arm. It is well known that patients given a placebo often show some relief from disease symptoms, but the extent to which placebo treatment of cancer patients leads to improvement in symptoms or quality of life, or in tumor responses, is not known. To investigate this question, Chvetzoff and Tannock (p. 19) searched the literature for randomized controlled trials in oncology with a placebo arm or a best supportive care arm. Their analysis of the outcomes of . . . [Full Text of this Article]

Postmenopausal Hormone Use and Mammographic Density

SV40 Exposure and Pleural Mesothelioma Incidence

Pap and HPV Testing and Cervical Cancer Risk

Pitfalls in the Use of Microarrays

Oltipraz Induction of Glutathione-S-Transferase




This article has been cited by other articles:


Home page
 BioinformaticsHome page
J. A. Koziol, A. C. Feng, Z. Jia, Y. Wang, S. Goodison, M. McClelland, and D. Mercola
The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis
Bioinformatics, January 1, 2009; 25(1): 54 - 60.
[Abstract] [Full Text] [PDF]